Catalent (NYSE:CTLT) Stock Rating Upgraded by StockNews.com

Catalent (NYSE:CTLT) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday.

Other analysts have also issued research reports about the stock. Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird restated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Nine equities research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $59.83.

Catalent Stock Performance

Shares of Catalent stock opened at $59.10 on Thursday. The company has a 50 day moving average price of $59.84 and a 200 day moving average price of $58.18. The firm has a market capitalization of $10.73 billion, a P/E ratio of -26.15, a PEG ratio of 2.35 and a beta of 1.16. Catalent has a 52 week low of $36.74 and a 52 week high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm posted ($0.10) EPS. The business’s revenue was up 4.2% compared to the same quarter last year. Sell-side analysts expect that Catalent will post 0.84 EPS for the current year.

Insider Activity

In related news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brooklyn Investment Group purchased a new stake in Catalent during the third quarter worth approximately $31,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent during the 2nd quarter worth approximately $42,000. Sentry Investment Management LLC acquired a new position in shares of Catalent in the 3rd quarter valued at $53,000. Longfellow Investment Management Co. LLC grew its position in shares of Catalent by 45.7% in the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.